Fate Therapeutics (FATE) Price & Analysis

Compare

1,212 Followers

FATE Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.66 - $4.20

Previous CloseN/A

Volume630.90K

Average Volume (3M)1.43M

Market Cap

$123.80M

Enterprise Value-$63.56M

Total Cash (Recent Filing)$240.43M

Total Debt (Recent Filing)$83.33M

Price to Earnings (P/E)―

Beta2.83

Next Earnings

Oct 30, 2025

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding114,633,020

10 Day Avg. Volume1,365,734

30 Day Avg. Volume1,433,637

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap-0.51

Enterprise Value/Revenue-4.77

Enterprise Value/Gross Profit2.99

Enterprise Value/Ebitda0.38

Forecast

1Y Price Target

$5.03

Price Target Upside365.74% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering11

Bulls Say, Bears Say

Bulls Say

Clinical Trial ResultsEarly efficacy data for FT819 in 5 patients are very encouraging, especially given its off-the-shelf nature and reduced conditioning differentiation.

Regulatory DevelopmentsFate plans to meet with the FDA to discuss potential pivotal study design in SLE/LN, aiming to remove the current hospitalization requirement post-treatment.

Safety ProfileFT819 was well-tolerated with no events of ICANS, GvHD or FT819-related SAEs, with all patients discharged 3-days post-dosing.

Bears Say

Clinical Trial LimitationsIt's still too early to adjudicate on FT819's clinical benefit due to a small sample size and limited follow-up in a majority of patients.

Potential RisksRisks include, but are not limited to: unknown clinical efficacy advantage with FT522 relative to other allogeneic and autologous CAR-T approaches; unexpected safety and immunogenicity concerns; partnership-related risks; negative reactions from regulatory agencies; and possible medium-term dilution risk.

Fate Therapeutics News

Fate Therapeutics’ Phase 1 Study: A New Hope for Autoimmune Diseases

Fate Therapeutics Inc (($FATE)) announced an update on their ongoing clinical study. Fate Therapeutics Inc. is conducting a...

6d ago

FATE

Cautious Outlook on Fate Therapeutics Amid Promising Data and Safety Concerns

In a report released today, Robert Burns from H.C. Wainwright reiterated a Hold rating on Fate Therapeutics, with...

1M ago

FATE

Cautious Hold on Fate Therapeutics: Promising Early Data for FT819 in Lupus, Awaiting Broader Evidence

Needham analyst Gil Blum has maintained their neutral stance on FATE stock, giving a Hold rating yesterday. Gil...

2M ago

FATE

Cautious Hold Rating on Fate Therapeutics Amid Promising but Preliminary CAR-T Therapy Data

Analyst Yanan Zhu from Wells Fargo maintained a Hold rating on Fate Therapeutics (FATE – Research Report) and...

2M ago

FATE

Fate Therapeutics announces updated data for FT819

Fate Therapeutics (FATE) announced new and updated clinical data from the first five patients dosed with FT819 for...

2M ago

FATE

Fate Therapeutics Approves Key Proposals at Annual Meeting

Fate Therapeutics ( ($FATE) ) just unveiled an update. On May 29, 2025, Fate Therapeutics held its Annual...

2M ago

FATE

Fate Therapeutics Reports Q1 2025 Financial Results

Fate Therapeutics Inc ( ($FATE) ) has released its Q1 earnings. Here is a breakdown of the information...

3M ago

FATE

Optimistic Buy Rating for Fate Therapeutics Driven by Promising FT819 Therapy and Pipeline Expansion

Analyst Daina Graybosch from Leerink Partners maintained a Buy rating on Fate Therapeutics (FATE – Research Report) and...

3M ago

FATE

Fate Therapeutics price target lowered to $4 from $5 at Baird

Baird lowered the firm’s price target on Fate Therapeutics (FATE) to $4 from $5 and keeps a Neutral...

3M ago

FATE

Fate Therapeutics price target lowered to $2 from $10 at Barclays

Barclays lowered the firm’s price target on Fate Therapeutics (FATE) to $2 from $10 and keeps an Overweight...

3M ago

FATE

Cautious Optimism for Fate Therapeutics Amid Promising Developments and Financial Stability

Wells Fargo analyst Yanan Zhu maintained a Hold rating on Fate Therapeutics (FATE – Research Report) yesterday and...

3M ago

FATE

Fate Therapeutics reports Q1 EPS (32c), consensus (38c)

Reports Q1 revenue $1.63M, consensus $1.18M. “We continue to be pleased with the initial clinical profile of our...

3M ago

FATE

FATE Upcoming Earnings Report: What to Expect?

Fate Therapeutics Inc (FATE) is scheduled to report 1st quarter earnings on 04/30/2025. Regarding Q1 estimates, Wall Street...

3M ago

FATE

Fate Therapeutics receives RMAT designation from FDA for FT819

Fate Therapeutics (FATE) announced that the U.S. Food and Drug Administration, FDA, granted Regenerative Medicine Advanced Therapy, RMAT,...

4M ago

FATE

FATE FAQ

What was Fate Therapeutics Inc’s price range in the past 12 months?

Fate Therapeutics Inc lowest stock price was $0.66 and its highest was $4.20 in the past 12 months.

What is Fate Therapeutics Inc’s market cap?

Fate Therapeutics Inc’s market cap is $123.80M.

When is Fate Therapeutics Inc’s upcoming earnings report date?

Fate Therapeutics Inc’s upcoming earnings report date is Oct 30, 2025 which is in 84 days.

How were Fate Therapeutics Inc’s earnings last quarter?

Currently, no data Available

Is Fate Therapeutics Inc overvalued?

According to Wall Street analysts Fate Therapeutics Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Fate Therapeutics Inc pay dividends?

Fate Therapeutics Inc does not currently pay dividends.

What is Fate Therapeutics Inc’s EPS estimate?

Fate Therapeutics Inc’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Fate Therapeutics Inc have?

Fate Therapeutics Inc has 114,633,020 shares outstanding.

What happened to Fate Therapeutics Inc’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Fate Therapeutics Inc?

Currently, no hedge funds are holding shares in FATE

Fate Therapeutics Stock Smart Score

Underperform

Fundamentals

Return on Equity

-49.23%

Trailing 12-Months

Asset Growth

-30.04%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Fate Therapeutics (FATE) Earnings & Revenues

Historic Earnings Reports

FATE Stock 12 Month Forecast

Average Price Target

$5.03

▲(365.74% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6":"$6","13":"$13","-1":"-$1","2.5":"$2.5","9.5":"$9.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$12.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5.03,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$5.03</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$2.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,2.5,6,9.5,13],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.14,1.9753846153846153,2.810769230769231,3.6461538461538456,4.481538461538461,5.316923076923077,6.152307692307692,6.987692307692307,7.823076923076923,8.65846153846154,9.493846153846155,10.32923076923077,11.164615384615384,{"y":12,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.14,1.439230769230769,1.7384615384615385,2.037692307692308,2.3369230769230773,2.6361538461538467,2.9353846153846157,3.2346153846153847,3.533846153846154,3.8330769230769235,4.132307692307693,4.431538461538462,4.730769230769232,{"y":5.03,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.14,1.2061538461538461,1.2723076923076921,1.3384615384615384,1.4046153846153846,1.4707692307692306,1.5369230769230768,1.603076923076923,1.669230769230769,1.7353846153846153,1.8015384615384615,1.8676923076923075,1.9338461538461538,{"y":2,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":7.08,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.09,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.68,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.88,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.43,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.96,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.65,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.3,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.12,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.76,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.24,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.3,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.14,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >